NCT03856684

Brief Summary

Despite the existence of an effective screening test (pap smear), cervical cancer is, every year in France, the cause of more than 3,000 new cases and 1,100 deaths. But, in France, 4 in 10 women are not screened or not often enough (nearly 7 millions women). It is therefore necessary to develop new strategies to reach these women. The etiological factor of this cancer is persistent infection with High-Risk Human PapillomaVirus (HR-HPV). Thereby, HPV-based tests could be alternative screening tests. Vaginal self-sampling with HR-HPV test is simpler and less intrusive than the pap smear. It has been shown that sending vaginal self-sampling kit (with HPV test) to unscreened women's home is a powerful means to increase the participation rate of cervical cancer screening. It seems interesting to explore methods to increase the efficiency of this strategy by optimizing the ratio of the number of kits used compared to the number of kits sent. Two approaches will be tested: a system "available on request" of the kit and / or the addition of an SMS (Short Message Service) reminder.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,400

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 26, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 27, 2019

Completed
12 months until next milestone

Study Start

First participant enrolled

February 11, 2020

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 14, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 20, 2021

Completed
Last Updated

October 29, 2021

Status Verified

October 1, 2021

Enrollment Period

1.4 years

First QC Date

February 26, 2019

Last Update Submit

October 28, 2021

Conditions

Keywords

vaginalself-samplingcervical cancer screeningPapillomavirusHPVHigh Risk Human papillomavirus Infectionpap smear

Outcome Measures

Primary Outcomes (1)

  • Participation / no participation to complete cervical cancer screening

    Complete cervical cancer screening is defined as one of the followings : * perform a pap smear * perform a vaginal self-sampling with negative HR-HPV test * perform a vaginal self-sampling with noninterpretable HR-HPV test result followed by a control pap smear (nine-month extension to do the pap smear after the sending of the HPV result) * perform a vaginal self-sampling with positive HR-HPV test result followed by a control pap smear (nine-month extension to do the pap smear after the sending of the HPV result)

    9 months after postal mail (with or without the kit) or SMS

Study Arms (4)

Self-sampling kit sent at home

ACTIVE COMPARATOR

Sending of a vaginal self-sampling kit at home

Behavioral: Self-sampling kit sent at home

Self-sampling kit sent at home + SMS reminder

EXPERIMENTAL

Sending of a vaginal self-sampling kit at home + a SMS reminder is sent if the woman do not (in 2 months) : * perform a pap smear * or send her vaginal self-sample to the laboratory * or contact the screening center to inform to an exclusion reason

Behavioral: Self-sampling kit sent at home + SMS reminder

Letter offering a self-sampling kit "on request"+ SMS reminder

EXPERIMENTAL

Sending of letter offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us. If they do ask for the kit, one kit is sending to their home. For these women, a SMS reminder is sent if the woman do not (in 2 months) : * perform a pap smear * or send her vaginal self-sample to the laboratory * or contact the screening center to inform to an exclusion reason

Behavioral: Letter offering a self-sampling kit "on request"+ SMS reminder

SMS offering a self-sampling kit "on request"+ SMS reminder

EXPERIMENTAL

Sending of SMS offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us. If they do ask for the kit, one kit is sending to their home. For these women, a SMS reminder is sent if the woman do not (in 2 months) : * perform a pap smear * or send her vaginal self-sample to the laboratory * or contact the screening center to inform to an exclusion reason

Behavioral: SMS offering a self-sampling kit "on request"+ SMS reminder

Interventions

Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Self-sampling kit sent at home

Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear. After 2 months without "return", a SMS reminder about the available self-sampling kit is sent to the woman. We call "return" : * the receipt of the vaginal self-sample at the laboratory * the performance of a pap smear * Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Self-sampling kit sent at home + SMS reminder

Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear. Women are invited to ask the kit online, on our website. For the women who ask the kit, after 2 months without "return", a SMS reminder about the available self-sampling kit is sent to the woman. We call "return" : * the receipt of the vaginal self-sample at the laboratory * the performance of a pap smear * Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Letter offering a self-sampling kit "on request"+ SMS reminder

Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request). Women are invited to ask the kit by answering "1" by SMS. For the women who ask the kit, after 2 months without "return", a SMS reminder about the available self-sampling kit is sent to the woman. We call "return" : * the receipt of the vaginal self-sample at the laboratory * the performance of a pap smear * Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

SMS offering a self-sampling kit "on request"+ SMS reminder

Eligibility Criteria

Age30 Years - 66 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • women from 30 to 66 years old
  • women living in french territorial division 37 ("Indre-et-Loire")
  • women with a mobile phone in database
  • women who do not perform a pap smear in the last 4 years
  • women who do not answer to a first "invitation" letter to perform a pap smear

You may not qualify if:

  • STOP SMS
  • HPV cervical pathology during treatment
  • Hysterectomy including cervix

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Crcdc-Cvl

Tours, 37044, France

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Julie BOYARD, MSc

    University Hospital of TOURS

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 26, 2019

First Posted

February 27, 2019

Study Start

February 11, 2020

Primary Completion

July 14, 2021

Study Completion

October 20, 2021

Last Updated

October 29, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations